Myelofibrosis

- Refractory hemorrhage in chronic subdural hematoma: primary myelofibrosis with subdural extramedullary hematopoiesis. Illustrative case
- Recurrent Stroke with Rapid Development of Intracranial Artery Stenosis and Subsequent Successful Mechanical Thrombectomy in Essential Thrombocythemia
- Extramedullary Hematopoiesis Presenting with Thoracic Spinal Cord Compression in a Young Adult with Thalassemia Major: A Case Report
- Spinal cord compression secondary to extramedullary haematopoiesis in transformed polycythaemia rubra vera
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis
- Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis
- Multiple neural tube defects: a rare combination of limited dorsal myeloschisis, diplomyelia with dorsal bony spur, sacral meningocoele, syringohydromyelia, and tethered cord
- Extramedullary hematopoiesis with spinal cord compression in pachydermoperiostosis

Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body's normal production of blood cells. Myelofibrosis causes extensive scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue.

Myelofibrosis is a rare bone marrow disorder characterized by the progressive replacement of the bone marrow with fibrous tissue. It is classified as a myeloproliferative neoplasm, a group of conditions characterized by the overproduction of blood cells. Myelofibrosis can occur as a primary condition (primary myelofibrosis) or as a result of another underlying condition (secondary myelofibrosis).

The exact cause of myelofibrosis is not fully understood. However, it is believed to be related to genetic mutations in the hematopoietic stem cells, which are responsible for producing blood cells. These mutations lead to abnormal cell growth and the accumulation of fibrous tissue in the bone marrow.

The main signs and symptoms of myelofibrosis can vary from person to person but may include:

Fatigue and weakness Enlarged spleen (splenomegaly), which can cause pain or a feeling of fullness in the abdomen Anemia (low red blood cell count), which can lead to shortness of breath and pale skin Easy bruising and bleeding tendencies due to decreased platelet count Bone pain or discomfort Night sweats Weight loss Frequent infections The diagnosis of myelofibrosis involves a combination of medical history evaluation, physical examination, blood tests, and bone marrow biopsy. Imaging studies such as ultrasound or magnetic resonance imaging (MRI) may be used to assess the size of the spleen.

Treatment options for myelofibrosis depend on the severity of symptoms and the overall health of the patient. The goal of treatment is to manage symptoms, improve quality of life, and address complications. Treatment approaches may include:

Supportive Care: This includes measures to manage symptoms such as anemia, infections, and pain. Blood transfusions, growth factors, and antibiotics may be used as necessary.

Drug Therapy: Certain medications, such as JAK inhibitors (e.g., ruxolitinib), may be prescribed to help

reduce spleen size, alleviate symptoms, and improve quality of life.

Stem Cell Transplantation: For eligible patients who have a suitable donor, a stem cell transplant may be considered as a potentially curative treatment option.

Radiation Therapy: In some cases, radiation therapy may be used to target and shrink an enlarged spleen.

Clinical Trials: Participation in clinical trials may be an option for patients who meet specific criteria and are willing to explore investigational therapies.

The management of myelofibrosis often involves a multidisciplinary team of healthcare professionals, including hematologists, oncologists, and supportive care specialists. Regular follow-up and monitoring are essential to assess disease progression, manage symptoms, and adjust treatment as needed.